Amazon backs federal bill to legalize marijuana and adjusts its drug testing policy for some workers
- Amazon on Tuesday said it backs federal legislation to legalize marijuana.
- The company also said it would adjust its drug testing policy for some workers to no longer screen for cannabis.
Amazon is throwing its weight behind federal legislation to legalize marijuana, while pledging to no longer screen some of its workers for the drug.
In a blog post Tuesday, Amazon's consumer boss Dave Clark said the company supports the Marijuana Opportunity Reinvestment and Expungement (MORE) Act, reintroduced in the House late last month. The measure would decriminalize cannabis at the federal level, expunge criminal records and invest in impacted communities.
"We hope that other employers will join us, and that policymakers will act swiftly to pass this law," Clark wrote.
Amazon also said it would adjust its corporate drug testing policy for some of its workers. The company will no longer include marijuana in its drug screening program for any positions not regulated by the Department of Transportation.
"In the past, like many employers, we've disqualified people from working at Amazon if they tested positive for marijuana use," Clark said. "However, given where state laws are moving across the U.S., we've changed course."
WATCH: A closer look at Amazon's warehouse injuries
Nuggets vs. Trail Blazers live blog: Real-time updates from Game 5 of the NBA playoffs first-round series – The Denver Post
Live updates, tweets, photos, analysis and more from the Nuggets playoff game against the Portland Trail Blazers at Ball Arena in Denver on June 1, 2021.
Mobile users, if you can’t see the live blog, tap here.
Elon Musk Tweets Violated Court Order Enacted In SEC Lawsuit Settlement – Report
Elon Musk twice violated a court order meant to prevent the Tesla CEO from allegedly using Twitter to manipulate the stock market, according to documents obtained by the Wall Street Journal on Tuesday.
The Securities and Exchange Commission alleged in a lawsuit that Musk committed fraud by tweeting about a potential buyout of his company in August 2018. Musk claimed that he was considering taking the company private and that he had secured funding to do so. It was reported at the time that the Saudi Arabian sovereign wealth fund was the source of that funding. Musk is the second-richest person on the planet, worth $156 billion according to Fortune.
As Musk wrote shortly thereafter in a public blog post:
I left the July 31st meeting with no question that a deal with the Saudi sovereign fund could be closed, and that it was just a matter of getting the process moving. This is why I referred to “funding secured” in the August 7th announcement.
Musk and Tesla paid $20 million apiece to settle the SEC suit. In addition to Musk stepping down as CEO, the agreement stipulated that the Tesla leader’s tweets would be reviewed by corporate lawyers before being posted.
The SEC warned Tesla in May 2020 that the company had failed “to enforce these procedures and controls despite repeated violations by Mr. Musk.” The letter added, “Tesla has abdicated the duties required of it by the court’s order.”
Read More About:
FDA Approves Novartis’ Cosentyx To Treat Plaque Psoriasis In Pediatric Patients
The U.S. Food and Drug Administration has approved Novartis’ (NVS) Cosentyx or secukinumab for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and older who are candidates for systemic therapy or phototherapy.
The Cosentyx approval was based on two Phase III studies evaluating the use of Cosentyx in children aged 6 to less than 18 years with plaque psoriasis. The safety profile reported in the trials was consistent with the safety profile reported in adult plaque psoriasis trials. No new safety signals were observed, Novartis said in a statement.
According to the company, the approved pediatric dosing for Cosentyx is 75 mg or 150 mg depending on the child’s weight at the time of dosing and is administered by subcutaneous injection every four weeks after an initial loading regimen.
Cosentyx is fully human biologic that directly inhibits interleukin-17A (IL-17A), a cornerstone cytokine involved in the inflammation and development of moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis (nr-axSpA)14,15,16.
NBA playoffs: Lakers’ Anthony Davis to miss Game 5 vs. Suns due to groin injury
Despite completing a pregame warmup and having extensive treatment on his strained left groin, Los Angeles Lakers forward Anthony Davis will miss Game 5 of the team's first-round series against the Phoenix Suns on Tuesday, the Lakers announced.
Davis completed an on-court workout about an hour before tipoff. Markieff Morris is slated to start in Davis' place.
"It’s a medical decision," Lakers coach Frank Vogel said before knowing Davis' availability. "If they feel he’s at risk with injuring it any further, then obviously they won’t let him be out there. But if they feel like it’s just about managing pain and he’s not more at risk than any other player, then he’ll be cleared. It’s going to be a medical decision."
OPINION: Can LeBron carry Lakers in playoffs if AD misses games?
NBA PLAYOFF SCHEDULE: First-round matchups, results, game times and TV info